News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Carisma Therapeutics Receives FDA Clearance of Investigational New Drug Application for CT-0525, a Novel CAR-M Cell Therapy
Having received a Study May Proceed notification from the FDA, Carisma plans to initiate a Phase 1 study in the months to come and to treat the first patient in the first half of 2024.
Penn’s Leadership Role in Philadelphia’s Rapidly Growing Life Sciences Industry Highlighted
Technical.ly published an article about the future of the growth of the life sciences in Philadelphia, highlighting Penn’s role in the development of the city as a strong tech hub.
PCI Ventures at Pennovation Works Annual Showcase Highlights Startup Growth and the Entrepreneurial Journey
During the program, Kamna Giare-Patel, CEO of Cerespectus and Thomas H., CEO of Peroxitech, shared their startup journeys and discussed their companies.
Technical.ly State of the Philadelphia Tech Economy Report Highlights Innovation Accomplishments at Penn
According to the report, Penn ranked within the top five largest research & development expenditures of US universities in 2021.
ViTToria Biotherapeutics Secures $15M
ViTToria is focused on developing novel CAR-T cell therapies that transcend the limitations of current cell therapies.
Office of the Vice Provost for Research Provides Funding to 2023 Discovering the Future and Accelerating From Lab to Market Research Grant Recipients
The Office of the Vice Provost for Research has provided nearly $1 million in funding to support research through Discovering the Future and Accelerating From Lab to Market research grant programs.
Gov. Josh Shapiro, President Liz Magill, and others from the Penn community Celebrate the new Penn Institute for RNA Innovation
“One of our great strategic advantages is our compact and contiguous campus, where 12 amazing schools and a world-class health system coexist just a short walk from one another,” said Magill.
Vivodyne Awarded Multiple Patents and Closed a $38 Million Seed Funding Round
Penn spinout Vivodyne closed a $38 million seed funding round led by Khosla Ventures.
Mitchell Lab: Lipid nanoparticles that deliver mRNA to T cells show potential treatment for autoimmune diseases
The goal of this platform is to engineer adoptive cell therapies inside of the body for specific autoimmune diseases.
Cabaletta Bio Receives Another FDA Clearance for IND application of CABA-201
The company plans to initiate a Phase 1/2 clinical trial of CABA-201 in two cohorts of patients with generalized myasthenia gravis (gMG).